STAT | Reporting from the frontiers of health and medicine Follow STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy. https://www.statnews.com/2026/08/20/capricor-therapeutics-duchenne-treatment-fda/ statnews.com
